Adaptin Bio (APTN) Research & Development (2024 - 2026)

Adaptin Bio has disclosed Research & Development across 3 years of filings, most recently posting $165577.0 for Q1 2026.

• Quarterly Research & Development rose 166.49% year-over-year to $165577.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (up 11.25% YoY) and the FY2025 annual result came in at $1.8 million, down 2.76% from the prior year.
• Research & Development eased to $165577.0 in Q1 2026, from $593035.0 in the prior quarter.
• Across five years, Research & Development topped out at $778664.0 in Q3 2025 and bottomed at $62133.0 in Q1 2025.
• The 3-year median for Research & Development is $340334.0 (2025), against an average of $418259.3.
• Year-over-year, Research & Development tumbled 68.77% in 2025 and soared 166.49% in 2026.
• Adaptin Bio's Research & Development stood at $258058.0 in 2024, then surged by 129.81% to $593035.0 in 2025, then tumbled by 72.08% to $165577.0 in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $165577.0, $593035.0, and $778664.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.